Analysts Set Emergent BioSolutions Inc. (NYSE:EBS) Price Target at $47.60
Analysts Set Emergent BioSolutions Inc. (NYSE:EBS) Price Target at $47.60
Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) has been given a consensus recommendation of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $47.60.
据MarketBeat.com报道，Emerent BioSolutions Inc.(纽约证券交易所代码：EBS-GET Rating)已被覆盖该公司的七家评级公司一致建议持有。四名分析师对该股的评级为持有，一名分析师对该公司的评级为买入。在过去一年追踪该股的券商中，12个月目标价的平均水平为47.60美元。
Several analysts recently commented on the company. Cowen dropped their price target on Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a research report on Monday. Cowen dropped their target price on shares of Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a report on Monday.
几位分析师最近对该公司发表了评论。考恩在周一的一份研究报告中将Emerent BioSolutions的目标价从30.00美元下调至29.00美元，并为该公司设定了“市场表现”评级。考恩在周一的一份报告中将Emerent BioSolutions的目标价从30.00美元下调至29.00美元，并为该公司设定了“市场表现”评级。
Institutional Investors Weigh In On Emergent BioSolutions
机构投资者参与新兴生物解决方案
Several hedge funds and other institutional investors have recently bought and sold shares of EBS. State of Alaska Department of Revenue lifted its stake in shares of Emergent BioSolutions by 1.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 33,825 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 430 shares during the last quarter. Covestor Ltd lifted its position in Emergent BioSolutions by 43.8% in the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 491 shares during the last quarter. Cutler Group LP boosted its stake in Emergent BioSolutions by 250.0% during the first quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 500 shares during the period. Kendall Capital Management raised its stake in shares of Emergent BioSolutions by 4.7% in the 1st quarter. Kendall Capital Management now owns 11,585 shares of the biopharmaceutical company's stock valued at $476,000 after acquiring an additional 525 shares during the period. Finally, Centaurus Financial Inc. boosted its position in shares of Emergent BioSolutions by 14.4% during the 2nd quarter. Centaurus Financial Inc. now owns 4,342 shares of the biopharmaceutical company's stock worth $135,000 after purchasing an additional 546 shares during the period. 81.54% of the stock is currently owned by institutional investors and hedge funds.
几家对冲基金和其他机构投资者最近买卖了EBS的股票。阿拉斯加州税务局在第二季度将其在Emerent BioSolutions的股份增加了1.3%。阿拉斯加州税务局在上个季度购买了430股后，现在拥有33,825股这家生物制药公司的股票，价值1,049,000美元。Covestor Ltd在第一季度将其在Emerent BioSolutions的头寸提高了43.8%。Covestor Ltd现在拥有这家生物制药公司1,612股股票，价值66,000美元，此前在上个季度又购买了491股。卡特勒集团在第一季度增持了250.0%的艾默生生物解决方案股份。卡特勒集团现在持有700股这家生物制药公司的股票，价值2.8万美元，在此期间又购买了500股。肯德尔资本管理公司在第一季度增持了Emerent BioSolutions的股份4.7%。肯德尔资本管理公司现在拥有这家生物制药公司11,585股股票，价值476,000美元，在此期间又购买了525股。最后，半人马座金融公司在第二季度将其在Emerent BioSolutions的股票头寸提高了14.4%。半人马座金融公司现在持有这家生物制药公司4,342股股票，价值135,000美元，在此期间又购买了546股。81.54%的股票目前由机构投资者和对冲基金持有。
Emergent BioSolutions Stock Down 0.7 %
Emerent BioSolutions股价下跌0.7%
Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($1.24). Emergent BioSolutions had a return on equity of 12.22% and a net margin of 6.02%. The firm had revenue of $242.70 million during the quarter, compared to analyst estimates of $268.77 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company's quarterly revenue was down 38.9% on a year-over-year basis. Equities analysts predict that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.
Emerent BioSolutions(纽约证券交易所代码：EBS-GET Rating)最近一次公布季度收益数据是在8月1日星期一。这家生物制药公司公布了本季度每股收益(EPS)(0.86美元)，低于普遍预期的0.38美元(1.24美元)。Emerent BioSolutions的股本回报率为12.22%，净利润率为6.02%。该公司本季度营收为2.427亿美元，而分析师预期为2.6877亿美元。去年同期，该公司公布的每股收益为0.33美元。该公司季度营收同比下降38.9%。股票分析师预测，Emerent BioSolutions本财年的每股收益将达到0.7%。
Emergent BioSolutions Company Profile
Emerent BioSolutions公司简介
(Get Rating)
(获取评级)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
Emerent BioSolutions Inc是一家生命科学公司，专注于提供准备和响应解决方案，以应对美国发生的意外、故意和自然发生的公共卫生威胁(PHTs)。该公司的产品涉及PHTs，包括化学、生物、辐射、核和爆炸物；新出现的传染病；旅行健康；以及新出现的健康危机和急性/紧急护理。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免费获取StockNews.com关于紧急生物解决方案(EBS)的研究报告
- 这家医疗设备制造商准备好继续反弹了吗？
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马？
- 具有有趣内幕活动的四只廉价股票
- 健康饮料制造商Celsius能否超越其Monster竞争对手？
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Emerent BioSolutions Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Emerent BioSolutions及相关公司的评级的每日摘要。